戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 may lead to potentially fatal EBV-associated posttransplant lymphoproliferative disease.
2 D4+ T cells reflects HVL patients at risk of posttransplant lymphoproliferative disease.
3               One EVR/rTAC patient developed posttransplant lymphoproliferative disease.
4                           We had no cases of posttransplant lymphoproliferative disease.
5  Burkitt's lymphoma, Hodgkin's lymphoma, and posttransplant lymphoproliferative disease.
6 ew the clinical and pathological spectrum of posttransplant lymphoproliferative disease.
7 as not been previously reported as a form of posttransplant lymphoproliferative disease.
8 ed with an increased risk for development of posttransplant lymphoproliferative disease.
9          One patient in each group developed posttransplant lymphoproliferative disease.
10 patients developed hematologic malignancies (posttransplant lymphoproliferative diseases, 18; Hodgkin
11 allogeneic CTL lines to treat EBV-associated posttransplant lymphoproliferative disease, a response r
12               We discuss this unique form of posttransplant lymphoproliferative disease and briefly r
13 ve Hodgkin disease but not in EBV-associated posttransplant lymphoproliferative disease and Hodgkin d
14 e first steps of in vivo immune control over posttransplant lymphoproliferative disease and lymphomas
15 tive for Epstein-Barr virus (EBV)-associated posttransplant lymphoproliferative disease and melanoma.
16 led lesions of Epstein-Barr virus-associated posttransplant lymphoproliferative disease and was chara
17 transplantation, (vii) graft disease, (viii) posttransplant lymphoproliferative disease, and (ix) sto
18 re (death or retransplant), acute rejection, posttransplant lymphoproliferative disease, and cardiac
19 cidence of reoperation, vascular thrombosis, posttransplant lymphoproliferative disease, and estimate
20 nt diabetes; 0.2%, avascular necrosis; 0.2%, posttransplant lymphoproliferative disease; and 0%, poly
21 nd reduce the risk of adverse events such as posttransplant lymphoproliferative disease are discussed
22 sia (ALH), that is pathologically similar to posttransplant lymphoproliferative disease associated wi
23                         No patient developed posttransplant lymphoproliferative disease, but 22 patie
24                                              Posttransplant lymphoproliferative disease can be treate
25 er LT for advanced-stage PSC was 18.7%, with posttransplant lymphoproliferative diseases, colorectal
26  associated with an increased risk of CMV or posttransplant lymphoproliferative disease compared with
27                   Epstein-Barr virus-induced posttransplant lymphoproliferative disease (EBV-PTLD) co
28        The fourteen patients with infections/posttransplant lymphoproliferative disease had a mean AT
29                                 Treatment of posttransplant lymphoproliferative disease has been augm
30 virus disease, graft-versus-host disease, or posttransplant lymphoproliferative disease has been obse
31 ic HCC and other tumors and various forms of posttransplant lymphoproliferative disease have occurred
32 Nonmelanoma skin cancer, Kaposi sarcoma, and posttransplant lymphoproliferative disease have standard
33 BV), as is demonstrated by the occurrence of posttransplant lymphoproliferative disease in immunosupp
34 ed with several human malignancies including posttransplant lymphoproliferative disease in immunosupp
35                             The incidence of posttransplant lymphoproliferative disease in patients r
36 ased risk of Epstein-Barr virus (EBV)-driven posttransplant lymphoproliferative disease, is an import
37 se (focal segmental glomerulosclerosis), and posttransplant lymphoproliferative disease may lead to t
38 pisodes of allograft rejection, incidence of posttransplant lymphoproliferative disease or coronary a
39 te with clinical confounders or a history of posttransplant lymphoproliferative disease or Epstein-Ba
40    Ten patients had no previous diagnosis of posttransplant lymphoproliferative disease (PT-LPD), whi
41      This study describes the development of posttransplant lymphoproliferative disease (PTLD) after
42                                              Posttransplant lymphoproliferative disease (PTLD) after
43  is considered to be a major risk factor for posttransplant lymphoproliferative disease (PTLD) and AI
44 t survival, episodes of rejection as well as posttransplant lymphoproliferative disease (PTLD) and gr
45                  Optimal upfront therapy for posttransplant lymphoproliferative disease (PTLD) arisin
46 ays an important role in the pathogenesis of posttransplant lymphoproliferative disease (PTLD) by per
47 EBV) DNA titers more than 1000 copies/mL and posttransplant lymphoproliferative disease (PTLD) develo
48 non-White ethnicity (p = 0.014) and previous posttransplant lymphoproliferative disease (PTLD) diagno
49 as to determine the incidence and hazard for posttransplant lymphoproliferative disease (PTLD) in a s
50  have previously reported a 10% incidence of posttransplant lymphoproliferative disease (PTLD) in ped
51                                              Posttransplant lymphoproliferative disease (PTLD) is a c
52                Epstein-Barr virus-associated posttransplant lymphoproliferative disease (PTLD) is a l
53                                              Posttransplant lymphoproliferative disease (PTLD) is a m
54                                              Posttransplant lymphoproliferative disease (PTLD) is a m
55                                              Posttransplant lymphoproliferative disease (PTLD) is a s
56                                              Posttransplant lymphoproliferative disease (PTLD) is a s
57                                              Posttransplant lymphoproliferative disease (PTLD) is a s
58 nosis of Epstein-Barr Virus (EBV)-associated posttransplant lymphoproliferative disease (PTLD) is imp
59 the subsequent development of EBV-associated posttransplant lymphoproliferative disease (PTLD) is the
60                          Optimal therapy for posttransplant lymphoproliferative disease (PTLD) remain
61                        Optimal management of posttransplant lymphoproliferative disease (PTLD) remain
62                                              Posttransplant lymphoproliferative disease (PTLD) remain
63  The incidence, risk factors, and outcome of posttransplant lymphoproliferative disease (PTLD) were e
64  Epstein-Barr virus (EBV) is associated with posttransplant lymphoproliferative disease (PTLD), and E
65 gnancies, including Burkitt's lymphoma (BL), posttransplant lymphoproliferative disease (PTLD), nasop
66  EBV type II and III latency tumors, such as posttransplant lymphoproliferative disease (PTLD), on EB
67 n increased risk of cytomegalovirus (CMV) or posttransplant lymphoproliferative disease (PTLD), we ex
68 s been linked to several diseases, including posttransplant lymphoproliferative disease (PTLD), which
69 elated primary central nervous system (PCNS) posttransplant lymphoproliferative disease (PTLD).
70         Transplant recipients are at risk of posttransplant lymphoproliferative disease (PTLD).
71 hat was lost 4 months after implantation for posttransplant lymphoproliferative disease (PTLD).
72 d to treat Epstein Barr virus (EBV)-positive posttransplant lymphoproliferative disease (PTLD).
73 isodes, cytomegalovirus (CMV) infection, and posttransplant lymphoproliferative disease (PTLD).
74 ce of rejection and/or gastrointestinal (GI) posttransplant lymphoproliferative disease (PTLD).
75  mortality following lung transplantation is posttransplant lymphoproliferative disease (PTLD).
76 l load after the diagnosis of EBV-associated posttransplant lymphoproliferative disease (PTLD).
77  have been used clinically in the therapy of posttransplant lymphoproliferative disease (PTLD).
78 V) plays a major role in the pathogenesis of posttransplant lymphoproliferative disease (PTLD).
79               Several interventions can cure posttransplant lymphoproliferative disease (PTLD); a seq
80 ad, EBV serology, and EBV-related morbidity (posttransplant lymphoproliferative disease [PTLD] or sym
81 virus, BK virus, and Epstein-Barr virus) and posttransplant lymphoproliferative disease remained low.
82 gnized cytotoxic T-lymphocyte epitopes in 25 posttransplant lymphoproliferative disease specimens fro
83 antation (OLT) one of the patients developed posttransplant lymphoproliferative disease, successfully
84 target Epstein-Barr virus strains present in posttransplant lymphoproliferative disease tumors.
85 e: unknown (seven), poor compliance (three), posttransplant lymphoproliferative disease, (two), hepat
86                                 Freedom from posttransplant lymphoproliferative disease was 96% at 1
87                             The incidence of posttransplant lymphoproliferative disease was equal in
88                                  EBV-related posttransplant lymphoproliferative disease was not obser
89               One (1.7%) case of polymorphic posttransplant lymphoproliferative disease was seen, whi
90                            The boy developed posttransplant lymphoproliferative disease, which resolv
91  (five Hodgkin's-like and one Burkitt's-like posttransplant lymphoproliferative disease) with restric
92  graft disease, (viii) chronic illness, (ix) posttransplant lymphoproliferative disease, (x) intracta